Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

[Long-term results of antiandrogenous therapy of prostate cancer].

Rakul SA, Galimov RD.

Vestn Khir Im I I Grek. 2012;171(4):79-83. Russian.

PMID:
23038922
2.

Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.

Spahn M, Briganti A, Capitanio U, Kneitz B, Gontero P, Karnes JR, Schubert M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group.

J Urol. 2012 Jul;188(1):84-90. doi: 10.1016/j.juro.2012.02.2572. Epub 2012 May 12.

PMID:
22578727
3.

Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors.

Zincke H, Bergstralh EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM, Barrett DM, Rife CC, Gonchoroff NJ.

Cancer. 1992 Jul 1;70(1 Suppl):311-23.

4.

[Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].

Kameoka H, Katayose K, Kumakawa K, Shiraiwa Y, Uchida H, Takahashi Y, Yazaki J, Yamaguchi O.

Gan To Kagaku Ryoho. 2005 Jan;32(1):57-63. Japanese.

PMID:
15675583
5.

Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.

Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Masuda H, Numao N, Ishikawa Y, Kohno A, Fukui I.

Jpn J Clin Oncol. 2012 Jun;42(6):541-7. doi: 10.1093/jjco/hys043. Epub 2012 Mar 28.

PMID:
22457326
6.

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S.

BJU Int. 2012 Feb;109 Suppl 1:22-9. doi: 10.1111/j.1464-410X.2011.10827.x. Review.

7.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

8.

Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.

Arcangeli G, Strigari L, Arcangeli S, Petrongari MG, Saracino B, Gomellini S, Papalia R, Simone G, De Carli P, Gallucci M.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):975-82. doi: 10.1016/j.ijrobp.2008.12.045. Epub 2009 Apr 22.

PMID:
19395188
9.

Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.

Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y; Prostate Cancer Study Group.

Int J Urol. 2004 May;11(5):295-303.

10.

Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.

Igdem S, Abacioglu U, Cetin I, Alco G, Akgun Z, Sengoz M, Bekiroglu N, Turkan S, Okkan S.

J BUON. 2009 Oct-Dec;14(4):629-34.

PMID:
20148454
11.
12.
13.

[Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy].

Miyamae K, Kitani K, Miyamoto K, Hamada S, Kawano T, Maehara A, Otsuka Y, Otsuka T, Hamada Y.

Nihon Hinyokika Gakkai Zasshi. 2009 Jul;100(5):570-5. Japanese.

PMID:
19663244
14.

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU.

J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.

PMID:
18413638
15.
17.

Androgen-deprivation therapy for prostate cancer.

Higano C.

Clin Prostate Cancer. 2003 Jun;2(1):22-3. No abstract available.

PMID:
15046679
18.

Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.

Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI.

J Urol. 2012 Jul;188(1):73-83. doi: 10.1016/j.juro.2012.03.005. Epub 2012 May 12.

PMID:
22578732
19.

Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy.

Karlsdottir A, Muren LP, Wentzel-Larsen T, Johannessen DC, Haukaas SA, Halvorsen OJ, Dahl O.

Acta Oncol. 2009;48(6):874-81. doi: 10.1080/02841860902974159.

PMID:
19488886
20.

Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.

Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden.

J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. doi: 10.1093/jnci/djq154. Epub 2010 Jun 18.

Supplemental Content

Support Center